HopeStage
Back to all studies
CompletedNCT02524899

Guanfacine Added to Cognitive Remediation for Schizotypal Personality

About this titleRead the official source — NCT02524899
Medication studyAges 18–65United StatesPersonality disorders
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2014
Recruitment status
Completed
Enrollment listed in the registry
45
Sponsor
Icahn School of Medicine at Mount Sinai
Sponsor type
University
Study type
Behavioral
Intervention type
Behavioural, Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT02524899
Official title
Show the full official title

Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Registry details
Registry conditions (original wording)

Schizotypal Personality Disorder; SPD

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Icahn School of Medicine at Mount Sinai, a university.

Did this study involve medication?

Yes. The study involved medication, including Guanfacine and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies